Medical Microbiology and Immunology , 194(1-2):55-9, doi: 10.1007/s00430-003-0212-z Pizzorne, J
Tonellotto L, Seremet T, Vernez M, Guenova E, Kuonen F
A systematic review published in the journal Drug and Alcohol Dependence provides a detailed analysis of the findings of available clinical trials that investigated the effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder
Its worth noting that Wegovy tends to cause more gastrointestinal side effects than some newer weight-loss medications
The weight-loss indication accounted for most semaglutide eligibility
Semaglutide addresses the neurobiological root of weight regainblunted GLP-1 signaling and dysregulated appetiterather than relying on willpower alone